Survival rates in the post-approval study for the Abiomed Impella RP right ventricular assist device were dramatically worse relative to the device’s clinical trial data. While 73% of the device’s users survived at least 30 days in the premarket study, just 17% have met this primary survival endpoint since the device went on the market in 2017. (MEDPAGETODAY)